Monoclonal antibody · Antagonist of Tissue factor pathway inhibitor (TFPI) · developed by Pfizer
Marstacimab is a human monoclonal IgG1 antibody that binds the Kunitz domain 2 of tissue factor pathway inhibitor (TFPI), neutralizing its activity to enhance coagulation. It is studied in hemophilia A or B.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 22, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07923981 | Phase 3 | Hemophilia A or B | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hemophilia A or B
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →